India-based firm Lupin has joined the pegfilgrastim parade with the FDA’s approval of Armlupeg (pegfilgrastim-unne), the seventh biosimilar for Amgen’s Neulasta approved in the US since 2018. Like ...

Data demonstrate a high degree of similarity between Armlupeg and the reference product. The Food and Drug Administration (FDA) has approved Armlupeg ™ (pegfilgrastim-unne), a biosimilar to Neulasta ® ...

New Delhi: Drug maker Lupin on Monday said it has received approval from the US health regulator for a biosimilar indicated for the treatment of neutropenia in cancer patients.The US Food and Drug ...

Global pharma major Lupin Limited (Lupin), announced that the United States Food and Drug Administration (FDA) has approved Armlupeg (pegfilgrastim-unne) 6 mg/0.6 mL injection for subcutaneous use in ...

Drug maker Lupin on Monday said it has received approval from the US health regulator for a biosimilar indicated for the treatment of neutropenia in cancer patients. The US Food and Drug ...

Armlupeg, a biosimilar to Neulasta, is approved for reducing febrile neutropenia in non-myeloid malignancy patients undergoing myelosuppressive chemotherapy. Lupin's FDA-approved facility in India ...

The drug decreases the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs. Nilesh Gupta, MD, Lupin, ...

With its growing oncology portfolio, which includes biosimilars and specialty care molecules, JAMP Pharma Group reaffirms its commitment to improving access to treatment for patients and supporting ...

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that Health Canada has granted marketing authorization for its Pegfilgrastim Injection, enabling ...

Neulasta (pegfilgrastim) is a brand-name injectable solution prescribed to treat radiation sickness and to help prevent infection due to chemotherapy. The cost of Neulasta with and without insurance ...